3.3.0.0 Im­mune-‍Me­di­at­ed Di­a­betes

This form, pre­vi­ous­ly called “in­sulin-‍de­pen­dent di­a­betes” or “ju­ve­nile-‍onset di­a­betes,” ac­counts for 5–10% of di­a­betes and is due to cel­lu­lar-‍me­di­at­ed au­toim­mune de­struc­tion of the pan­cre­at­ic β-‍cells. Au­toim­mune mark­ers in­clude islet cell au­toan­ti­bod­ies and au­toan­ti­bod­ies to GAD (GAD65), in­sulin, the ty­ro­sine phos­phatases IA-2 and IA-2β, and ZnT8. Type 1 di­a­betes is defined by the pres­ence of one or more of these au­toim­mune mark­ers. The dis­ease has strong HLA as­so­ci­a­tions, with link­age to the DQA and DQB genes. These HLA-DR/DQ al­le­les can be ei­ther pre­dis­pos­ing or pro­tec­tive.

The rate of β-cell de­struc­tion is quite vari­able, being rapid in some in­di­vid­u­als (main­ly in­fants and chil­dren) and slow in oth­ers (main­ly adults). Chil­dren and ado­les­cents may pre­sent with DKA as the first man­i­fes­ta­tion of the dis­ease. Oth­ers have mod­est fast­ing hy­per­glycemia that can rapid­ly change to se­vere hy­per­glycemia and/‍or DKA with in­fec­tion or other stress. Adults may re­tain sufficient β-cell func­tion to pre­vent DKA for many years; such in­di­vid­u­als even­tu­al­ly be­come de­pen­dent on in­sulin for sur­vival and are at risk for DKA. At this lat­ter stage of the dis­ease, there is lit­tle or no in­sulin se­cre­tion, as man­i­fest­ed by low or unde­tectable lev­els of plas­ma C-‍pep­tide. Im­mune-‍me­di­at­ed di­a­betes com­monly oc­curs in child­hood and ado­les­cence, but it can occur at any age, even in the 8th and 9th decades of life.

Au­toim­mune de­struc­tion of β-‍cells has mul­ti­ple ge­net­ic predispo­si­tions and is also re­lat­ed to en­vi­ron­men­tal fac­tors that are still poor­ly defined. Al­though pa­tients are not typ­i­cal­ly obese when they pre­sent with type 1 di­a­betes, obe­si­ty should not pre­clude the di­ag­no­sis. Peo­ple with type 1 di­a­betes are also prone to other au­toim­mune dis­or­ders such as Hashimo­to thy­roidi­tis, Graves dis­ease, Ad­di­son dis­ease, celi­ac dis­ease, vi­tili­go, au­toim­mune hep­ati­tis, myas­the­nia gravis, and per­ni­cious ane­mia (see Sec­tion 4 “Com­pre­hen­sive Med­i­cal Eval­u­a­tion and As­sess­ment of Co­mor­bidi­ties”).